Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed FCF Margin for 5 consecutive years, with 26.35% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 1109.0% year-over-year to 26.35%, compared with a TTM value of 20.13% through Dec 2025, up 1413.0%, and an annual FY2025 reading of 20.13%, up 1413.0% over the prior year.
  • FCF Margin was 26.35% for Q4 2025 at Kiniksa Pharmaceuticals International, up from 18.29% in the prior quarter.
  • Across five years, FCF Margin topped out at 62.57% in Q3 2022 and bottomed at 236.13% in Q3 2021.
  • Average FCF Margin over 5 years is 16.32%, with a median of 4.99% recorded in 2024.
  • The sharpest move saw FCF Margin skyrocketed 29870bps in 2022, then crashed -3726bps in 2023.
  • Year by year, FCF Margin stood at 102.08% in 2021, then surged by 108bps to 7.78% in 2022, then crashed by -34bps to 5.12% in 2023, then soared by 198bps to 15.26% in 2024, then skyrocketed by 73bps to 26.35% in 2025.
  • Business Quant data shows FCF Margin for KNSA at 26.35% in Q4 2025, 18.29% in Q3 2025, and 17.72% in Q2 2025.